CD5 表达对复发/难治性弥漫大 B 细胞淋巴瘤 CAR-T 细胞治疗结局的影响

Impact of CD5 expression on outcomes for chimeric antigen receptor-T cell therapy in relapsed and refractory diffuse large B-cell lymphoma.

Epcoritamab 在 CAR-T 治疗后复发 CD19-CD5+ 弥漫大 B 细胞淋巴瘤中的有效且安全给药

The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.

该病例凸显了 epcoritamab 联合减瘤治疗用于治疗 CAR-T 难治性 CD19 阴性 DLBCL 的潜力。

通过光学与 PSMA 靶向 PET 成像开发原位 CAR-T 细胞方案

Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging.

一例 CAR-T 细胞治疗伴持续性 CAR-T 细胞的 DLBCL 早期孤立性中枢神经系统复发的成功病例

A case of successful CAR-T cell therapy for early isolated CNS recurrence of DLBCL with persistent CAR-T cells.

慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中微小/可测量病灶的流式细胞术分析

Minimal/Measurable Disease Analysis in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma by Flow Cytometry.